How did Inmazeb and Ebanga compare with remdesivir and ZMapp in Ebola treatment trials?

Created from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.

Ebolavirus and Ebola virus disease — Ebola Numerous filamentous ebolavirus particles (blue) budding from a chronically-infected VERO E6 cell (yellow-green) in this digitally colorized scanning electron micrograph produced by the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

In clinical trials conducted during the 2018–2020 Ebola outbreak, the targeted antibody therapies Inmazeb (REGN-EB3) and Ebanga (mAb114) were found to be more effective at reducing mortality compared to the antiviral drug remdesivir and the antibody mixture ZMapp.1

While ZMapp was used during the 2014–2016 outbreak, its effectiveness remained unclear at that time. Remdesivir, which functions by inhibiting viral replication, was also investigated as a potential treatment for Ebola before being studied for other viral infections. Following the successful results of the 2018–2020 trials, Inmazeb and Ebanga received approval from the U.S. Food and Drug Administration in 2020 as effective treatments for the Zaire strain of the Ebola virus.2134